Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a dose-escalating U.S. Phase I trial, 8 of 49 (16%) patients given
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury